RxDoctor Payments Data

Nicolas Doan van, MD

Interventional Cardiology · Fountain Valley, CANPI 1801922521

Payments from drug & device makers

$5,238in general payments, 2019–2025

Across 242 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Abbott$497
  • Pfizer$468
  • Boehringer Ingelheim$348
  • Johnson & Johnson$326
  • Atricure, Inc.$263
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,13998%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,238 in reported general payments places this provider in the 35th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$199,394
Medicare patients
413
Services billed
2,015

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban431$520,133
EntrestoSacubitril/Valsartan105$134,683
XareltoRivaroxaban112$115,429
BrilintaTicagrelor33$29,682
MultaqDronedarone Hcl33$27,248
FarxigaDapagliflozin Propanediol22$26,383
Repatha SureclickEvolocumab24$21,488
JardianceEmpagliflozin11$18,502
VascepaIcosapent Ethyl18$11,106
Ranolazine ErRanolazine40$7,469
Metoprolol Succinate490$6,883
Ezetimibe321$5,363
Losartan Potassium471$4,754
Flecainide Acetate105$4,580
Icosapent Ethyl18$4,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$468$520,133431 claims
NovartisEntresto$1,435$134,683105 claims
Johnson & JohnsonXarelto$326$115,429112 claims
AstraZenecaBrilinta, Farxiga$183$56,06455 claims
Sanofi-aventis U.S. LLCMultaq$89$27,24833 claims
Boehringer IngelheimJardiance$348$18,50211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →